CD274 and endometrial cancer: In contrast to this Ramirez et al. recently revealed an advantage of ICi treatment with Pembrolizumab independently of PD-L1 expression according to CPS score in the first-line setting [21].There are limited data regarding clinicopathologic characteristics and PD1/PD-L1 status of endometrial cancer patients in respect to different scoring techniques.